Literature DB >> 34156439

Intratumoral T cells have a differential impact on FDG-PET parameters in follicular lymphoma.

Karthik Nath1, Soi-Cheng Law1, Muhammed B Sabdia1, Jay Gunawardana1, Lilia M de Long1, David Sester2, Mohamed Shanavas1, Hennes Tsang1, Joshua W D Tobin1, Sarah-Jane Halliday3, Annette Hernandez3, Donna Cross3, Robert J Bird3, Sanjiv Jain4, Colm Keane1,3, Dipti Talaulikar5,6, Judith Trotman7,8, Phillip Law9, Maher K Gandhi1,3.   

Abstract

Data on the prognostic impact of pretherapy 18F-fluorodeoxyglucose-positron emission tomography (FDG-PET) in follicular lymphoma (FL) is conflicting. The predictive utility of pretherapy total metabolic tumor volume (TMTV) and maximum standardized uptake value (SUVmax) on outcome appears to vary between regimens. Chemoimmunotherapies vary in the extent of T-cell depletion they induce. The role of intratumoral T cells on pretherapy FDG-PET parameters is undefined. We assessed pretherapy FDG-PET parameters and quantified intratumoral T cells by multiple methodologies. Low intratumoral T cells associated with approximately sixfold higher TMTV, and FL nodes from patients with high TMTV showed increased malignant B-cell infiltration and fewer clonally expanded intratumoral CD8+ and CD4+ T-follicular helper cells than those with low TMTV. However, fluorescently labeled glucose uptake was higher in CD4+ and CD8+ T cells than intratumoral B cells. In patients with FDG-PET performed prior to excisional biopsy, SUVmax within the subsequently excised node associated with T cells but not B cells. In summary, TMTV best reflects the malignant B-cell burden in FL, whereas intratumoral T cells influence SUVmax. This may contribute to the contradictory results between the prognostic role of different FDG-PET parameters, particularly between short- and long-term T-cell-depleting chemoimmunotherapeutic regimens. The impact of glucose uptake in intratumoral T cells should be considered when interpreting pretherapy FDG-PET in FL.
© 2021 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34156439     DOI: 10.1182/bloodadvances.2020004051

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  3 in total

Review 1.  Follicular lymphoma: is there an optimal way to define risk?

Authors:  Carla Casulo
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2021-12-10

Review 2.  Time for an individualized approach to first-line management of follicular lymphoma.

Authors:  Guillaume Cartron; Judith Trotman
Journal:  Haematologica       Date:  2022-01-01       Impact factor: 9.941

3.  Circulating tumor DNA predicts therapeutic outcome in mantle cell lymphoma.

Authors:  Rahul Lakhotia; Christopher Melani; Kieron Dunleavy; Stefania Pittaluga; Nakhle Saba; Liza Lindenberg; Esther Mena; Ethan Bergvall; Andrea Nicole Lucas; Allison Jacob; Erik Yusko; Seth M Steinberg; Elaine S Jaffe; Adrian Wiestner; Wyndham H Wilson; Mark Roschewski
Journal:  Blood Adv       Date:  2022-04-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.